Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
As the American Massage Therapy Association® (AMTA®) marks its 15th annual National Massage Therapy Awareness Week October 23 – October 29, 2011, more consumers are using massage therapy for pain relief and other health issues. In fact, according to a recent consumer survey commissioned by AMTA, consumers are progressively integrating massage therapy into their regular health maintenance routines.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52739-american-massage-therapy-association-amta-pain-relief-health-benefits
The launch of the fall television season is underway and with it, the influx of commercial interruptions. Lexus is offering an alternative to the traditional 30-minute sitcom with the debut of its fourth season of L Studio. The popular broadband channel, which has delivered such award-winning entertainment as “Web Therapy” and “Puppy Love,” is now partnering with Academy Award-winning screenwriter Diablo Cody (“Juno”) to debut her Web series “Red Band Trailer.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/52359-lexus-l-studio-diablo-cody-red-band-trailer-celebrity-interviews
Pet owner Judy Bernath loves her 11-year-old cat Billy, so when she noticed he had become lethargic, started losing weight and drastically changed from the happy cat he had once been, she made a visit to see her veterinarian Dr. David Bruyette, medical director at VCA West Los Angeles Animal Hospital. The VCA team diagnosed Billy as being hyperthyroid within a few days, and Dr. Bruyette shared conventional therapy options with Judy, like radiation therapy, daily pharmaceuticals and surgery. In addition, he discussed and ultimately recommended a new and different approach for Billy’s case – nutritional management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51765-hills-pet-nutrition-launches-new-pet-food-for-hyperthyroid-cats
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Is your dog a hero? American Humane Association’s Hero Dog Awards™ national search kicks off today at www.herodogawards.org.
The Film & Television Unit of American Humane Association is heading up the search for America’s Hero Dogs. Dogs may be nominated in eight categories: Law Enforcement and Arson Dogs; Service Dogs; Therapy Dogs; Military Dogs; Guide Dogs; Search and Rescue Dogs; Hearing Dogs; and Emerging Hero Dogs. Finalists in each category will be selected by the public from the pool of contestants, and the winners will be announced at the first-ever American Humane Association Hero Dog Awards™ celebrity gala, presented by CESAR® Canine Cuisine, at the Beverly Hilton Hotel in Los Angeles, California on October 1, 2011.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/americanhumane/49289/
Imagine your world in silence. Imagine the colour and vibrancy of your world sapped and living in silence. Imagine without communication how your world would be colourless, and you would feel boxed in, unable to communicate, share, grow. Your voice expresses who you are in the world, can you imagine losing your voice? Can you imagine your world in silence?
GivingvoiceUK and the giving voice campaign aim to secure access to speech and language therapy for all those who need it. Speech and language therapy means that people don't need to live in silence. No-one should have to live without speech; lend you support at http://www.givingvoiceuk.org/addyourvoice
http://acne.gd/clear-remedy/
I am glad I was in a position to attempt this item with a reduced cost, because frankly it did not reside up to its billing. The therapy system is according to salicylic acid and other
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
